The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.
The aim of this study is to test the therapeutic efficacy of immunomodulation with lobenzarit disodium (CCA) upon coxsackievirus B3 (CB3) myocarditis. Two-week-old C3H/He mice were inoculated with 10(3) plaque-forming units of CB3. CCA, 2.5 mg/kg per day, was administered subcutaneously daily on days 0-14 (Experiment I; group 2) and days 14-28 (Experiment II; group 4). Both treated groups were compared to infected controls (groups 1 and 3). For the analysis of splenic lymphocyte subsets, additional mice in untreated and treated groups were killed on day 7, and the percentages of Thy 1.2 (CD3), L3T4 (CD4) and, Ly 2 (CD8) subsets were analyzed by laser flow cytometry (Experiment III). In Experiment I, the survival rate did not differ significantly between groups 1 and 2. Cellular infiltration in the CCA group was less severe. Myocardial virus titers and serum neutralizing antibody titers did not differ significantly between the two groups. In Experiment II, the survival rates between the two groups did not differ significantly. Myocardial necrosis in the CCA group was less severe compared to the control. In Experiment III, the percentages of Thy 1.2 (CD3) and L3T4 subsets (CD4) of the treated group were significantly higher than those of the control group. Thus, CCA increased splenic T cells and improved cardiac pathology in acute murine CB3 myocarditis.
Second Department of Internal Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
H
H
Takada
C
C
Kishimoto
Y
Y
Kuroki
I
I
Matsushita
Y
Y
Hiraoka
M
M
Kurokawa
H
H
Ochiai
S
S
Sasayama
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis*; D003384:Coxsackievirus Infections / Q000276:immunology / Q000473:pathology*; D029822:Enterovirus B, Human / Q000187:drug effects* / Q000276:immunology; D005455:Fluorescent Antibody Technique; D007958:Leukocyte Count / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009205:Myocarditis / Q000276:immunology / Q000473:pathology*; D009206:Myocardium / Q000276:immunology / Q000473:pathology; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D062367:ortho-Aminobenzoates; C015735:lobenzarit